Antibody therapies
Antibody therapies has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 22, 2026: “A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA”.
1 paper studies it2 findingsUpdated
See all 1 papers on antibody therapies
What did studies of antibody therapies find?
2Studies of antibody therapies measured 2 outcomes: cognitive decline and amyloid plaque.
Cognitive decline
downin humans1
1 study
Cognitive decline
downin humans1
Antibody therapies decrease cognitive decline in people with Alzheimer's disease who are mildly impaired.
Reviewin people with Alzheimer's disease who are mildly impaired
Amyloid plaque
downin humans1
1 study
Amyloid plaque
downin humans1
Antibody therapies decrease amyloid plaque in people with Alzheimer's disease who are mildly impaired.
Reviewin people with Alzheimer's disease who are mildly impairedbrain